en
Scientific article
English

Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

ContributorsThe Polaris Observatory Collaborators
CollaboratorsNegro, Francesco
Published inThe Lancet Gastroenterology & Hepatology, vol. 3, no. 6, p. 383-403
Publication date2018
Abstract

The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate viral hepatitis by 2030. Although no virological cure exists for hepatitis B virus (HBV) infection, existing therapies to control viral replication and prophylaxis to minimise mother-to-child transmission make elimination of HBV feasible. We aimed to estimate the national, regional, and global prevalence of HBsAg in the general population and in the population aged 5 years in 2016, as well as coverage of prophylaxis, diagnosis, and treatment.

Keywords
  • Adult
  • Antiviral Agents/therapeutic use
  • Child
  • Preschool
  • Delphi Technique
  • Global Health
  • Hepatitis B Surface Antigens/blood
  • Hepatitis B
  • Chronic/drug therapy/epidemiology/prevention & control/transmission
  • Humans
  • Infectious Disease Transmission
  • Vertical/prevention & control
  • Mass Vaccination
  • Prevalence
  • Viral Vaccines
Citation (ISO format)
The Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. In: The Lancet Gastroenterology & Hepatology, 2018, vol. 3, n° 6, p. 383–403. doi: 10.1016/S2468-1253(18)30056-6
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal2468-1253
276views
0downloads

Technical informations

Creation10/15/2019 4:17:00 PM
First validation10/15/2019 4:17:00 PM
Update time03/15/2023 6:10:53 PM
Status update03/15/2023 6:10:52 PM
Last indexation01/17/2024 6:30:56 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack